Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh Acquires 22,222 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh purchased 22,222 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were purchased at an average price of C$2.31 per share, for a total transaction of C$51,332.82.

Fennec Pharmaceuticals Stock Up 0.8 %

Fennec Pharmaceuticals stock opened at C$14.32 on Wednesday. Fennec Pharmaceuticals Inc. has a twelve month low of C$9.27 and a twelve month high of C$15.43. The stock has a 50 day moving average of C$13.50 and a two-hundred day moving average of C$12.59. The company has a current ratio of 3.29, a quick ratio of 10.17 and a debt-to-equity ratio of 881.09. The stock has a market capitalization of C$387.21 million, a price-to-earnings ratio of -14.04 and a beta of 0.35.

Fennec Pharmaceuticals (TSE:FRX) last posted its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported C($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of C$0.02 by C($0.16). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a negative net margin of 75.50%. The company had revenue of C$13.25 million for the quarter, compared to analyst estimates of C$12.88 million. As a group, research analysts expect that Fennec Pharmaceuticals Inc. will post 0.4202312 earnings per share for the current year.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.